French biotech to infuse TargeGen
Paris-based pharmaceutical giant Sanofi-Aventis agreed Wednesday to pay up to $560 million for TargeGen, a San Diego biotech company that is developing a drug to treat leukemia, lymphoma and other blood disorders.
Original post by macular degeneration – Google News
(click on the author link above to see full post)